Barinthus Biotherapeutics plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $25.4M
- Price
- $0.6217
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.54%
- Volume
- 11.7K
About
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Quick stats
Shares outstanding40.8M
Computed float22.7M
Float / shares55.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001828185
Websitehttps://www.barinthusbio.com
AI Summary
AI-generated1/4
standardmixedearnings
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
Barinthus Bio reported Q2 cash of $59.6 million, down from $67.2 million in the prior quarter, with a net loss of $10.6 million or $0.26 per share driven by R&D and G&A expenses.
The company completed enrollment in the Phase 1 AVALON trial for VTP-1000 in celiac disease, with topline data from the multiple ascending dose cohort expected in the fourth quarter of 2026.
Corporate developments include progress on the proposed merger with Clywedog Therapeutics—expected to close in the second half of 2026—and a Nasdaq listing transfer to the Capital Market after receiving an extension to regain bid price compliance.
Red flags
- Listing transferred from Nasdaq Global Market to Nasdaq Capital Market
- Received Nasdaq extension to regain bid price compliance (180 days)